BRPI0408423A - composições farmacêuticas compreendendo uma combinação de rapamicina ou seus derivados e pimecrolimus para o tratamento de doenças mediadas imunologicamente e por inflamação - Google Patents

composições farmacêuticas compreendendo uma combinação de rapamicina ou seus derivados e pimecrolimus para o tratamento de doenças mediadas imunologicamente e por inflamação

Info

Publication number
BRPI0408423A
BRPI0408423A BRPI0408423-3A BRPI0408423A BRPI0408423A BR PI0408423 A BRPI0408423 A BR PI0408423A BR PI0408423 A BRPI0408423 A BR PI0408423A BR PI0408423 A BRPI0408423 A BR PI0408423A
Authority
BR
Brazil
Prior art keywords
treatment
immunologically
combination
pharmaceutical compositions
rapamycin
Prior art date
Application number
BRPI0408423-3A
Other languages
English (en)
Inventor
Henrietta Moore
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33032928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0408423(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0306070A external-priority patent/GB0306070D0/en
Priority claimed from GB0306868A external-priority patent/GB0306868D0/en
Priority claimed from GB0319226A external-priority patent/GB0319226D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0408423A publication Critical patent/BRPI0408423A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

"COMPOSIçõES FARMACêUTICAS COMPREENDENDO UMA COMBINAçãO DE RAPAMICINA OU SEUS DERIVADOS E PIMECROLIMUS PARA O TRATAMENTO DE DOENçAS MEDIADAS IMUNOLOGICAMENTE E POR INFLAMAçãO". A presente invenção refere-se a composições farmacêuticas compreendendo em combinação rapamicina ou um derivado de rapamicina e um composto de fórmula I, por exemplo útil para o tratamento de doenças inflamatórias e doenças mediadas imunologicamente, inclusive doenças autoimunes.
BRPI0408423-3A 2003-03-17 2004-03-16 composições farmacêuticas compreendendo uma combinação de rapamicina ou seus derivados e pimecrolimus para o tratamento de doenças mediadas imunologicamente e por inflamação BRPI0408423A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0306070A GB0306070D0 (en) 2003-03-17 2003-03-17 Organic compounds
GB0306868A GB0306868D0 (en) 2003-03-25 2003-03-25 Organic compounds
GB0319226A GB0319226D0 (en) 2003-08-15 2003-08-15 Organic compounds
PCT/EP2004/002714 WO2004082681A1 (en) 2003-03-17 2004-03-16 Pharmaceutical compositions comprising a combination of rapamycin or its derivative and pimecrolimus for the treatment of inflammation- and ummunologically-mediated diseases

Publications (1)

Publication Number Publication Date
BRPI0408423A true BRPI0408423A (pt) 2006-03-21

Family

ID=33032928

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408423-3A BRPI0408423A (pt) 2003-03-17 2004-03-16 composições farmacêuticas compreendendo uma combinação de rapamicina ou seus derivados e pimecrolimus para o tratamento de doenças mediadas imunologicamente e por inflamação

Country Status (26)

Country Link
US (1) US20060154952A1 (pt)
EP (1) EP1608368B8 (pt)
JP (1) JP2006515017A (pt)
KR (1) KR100855140B1 (pt)
AR (1) AR043504A1 (pt)
AT (1) ATE409479T1 (pt)
AU (1) AU2004222563B2 (pt)
BR (1) BRPI0408423A (pt)
CA (2) CA2517671A1 (pt)
CL (1) CL2004000535A1 (pt)
DE (1) DE602004016830D1 (pt)
EC (1) ECSP056006A (pt)
ES (1) ES2315648T3 (pt)
HK (1) HK1086743A1 (pt)
HR (1) HRP20050800A2 (pt)
IS (1) IS8028A (pt)
MA (1) MA27671A1 (pt)
MX (1) MXPA05009934A (pt)
MY (1) MY137868A (pt)
NO (1) NO20054778L (pt)
PE (1) PE20050313A1 (pt)
PL (1) PL1608368T3 (pt)
PT (1) PT1608368E (pt)
TN (1) TNSN05197A1 (pt)
TW (2) TW200835484A (pt)
WO (1) WO2004082681A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005302004A1 (en) * 2004-10-28 2006-05-11 Wyeth Use of an mTOR inhibitor in treatment of uterine leiomyoma
AU2013205002B2 (en) * 2008-03-21 2016-09-15 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
CA2719134C (en) * 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
EP2382228B1 (en) 2009-01-21 2020-08-26 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
RU2449806C1 (ru) * 2010-11-30 2012-05-10 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ лечения красного плоского лишая слизистой оболочки полости рта
ES2797376T3 (es) 2013-01-24 2020-12-02 Palvella Therapeutics Inc Composiciones para la administración transdérmica de inhibidores de mTOR
RU2707285C2 (ru) 2013-10-08 2019-11-26 ЭйАй ТЕРАПЬЮТИКС, ИНК. Рапамицин для лечения лимфангиолейомиоматоза
MX2016012712A (es) * 2014-04-04 2017-03-31 Lam Therapeutics Inc Una formulacion de rapamicina inhalable para tratar afecciones relacionadas con la edad.
EP3209330B1 (en) 2014-10-07 2022-02-23 AI Therapeutics, Inc. An inhalable sirolimus formulation for the treatment of pulmonary hypertension
UA126270C2 (uk) 2015-04-10 2022-09-14 Емджен Інк. Мутеїни інтерлейкіну-2 для росту регуляторних t-клітин
IL302385B1 (en) 2017-01-06 2024-02-01 Palvella Therapeutics Inc Non-aqueous preparations of mTOR inhibitors and methods of use
EP3817743A4 (en) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0427680T3 (da) * 1989-11-09 1995-12-18 Sandoz Ltd Heteroatom-holdige cykliske forbindelser
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
ATE340586T1 (de) * 1996-07-30 2006-10-15 Novartis Pharma Gmbh Pharmazeutische zusammensetzungen zur behandlung der transplantatabstossung sowie der autoimmun- oder entzündlichen zustände
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
EP1389108A2 (en) * 2001-05-09 2004-02-18 Novartis AG Methods for selective immunomodulation using pimecrolimus
IL162719A0 (en) * 2002-01-10 2005-11-20 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin andderivatives thereof
CN1318103C (zh) * 2002-05-09 2007-05-30 亨莫特克股份有限公司 酰化多糖作为血液相容性涂层用于预防或减轻再狭窄的应用

Also Published As

Publication number Publication date
AR043504A1 (es) 2005-08-03
EP1608368A1 (en) 2005-12-28
AU2004222563A1 (en) 2004-09-30
PL1608368T3 (pl) 2009-03-31
NO20054778L (no) 2005-12-19
EP1608368B8 (en) 2009-06-10
TW200503703A (en) 2005-02-01
TW200835484A (en) 2008-09-01
HK1086743A1 (en) 2006-09-29
PE20050313A1 (es) 2005-06-14
PT1608368E (pt) 2009-01-27
US20060154952A1 (en) 2006-07-13
KR20050110023A (ko) 2005-11-22
JP2006515017A (ja) 2006-05-18
CL2004000535A1 (es) 2005-01-14
CA2517671A1 (en) 2004-09-30
TNSN05197A1 (en) 2007-06-11
AU2004222563B2 (en) 2006-11-02
MY137868A (en) 2009-03-31
DE602004016830D1 (de) 2008-11-13
KR100855140B1 (ko) 2008-08-28
WO2004082681A1 (en) 2004-09-30
MXPA05009934A (es) 2006-03-21
IS8028A (is) 2005-09-15
ATE409479T1 (de) 2008-10-15
CA2633287A1 (en) 2004-09-30
HRP20050800A2 (en) 2006-11-30
NO20054778D0 (no) 2005-10-17
ES2315648T3 (es) 2009-04-01
ECSP056006A (es) 2006-01-27
WO2004082681B1 (en) 2004-11-25
EP1608368B1 (en) 2008-10-01
MA27671A1 (fr) 2005-12-01

Similar Documents

Publication Publication Date Title
WO2005066163A3 (en) Thiophene derivatives as chk 1 inihibitors
TW200718422A (en) 1,6-Dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
CY1112733T1 (el) Ενωσεις ιμιδαζο [4,5-c]πυριδινης και μεθοδοι αντι-ιικης θεραπειας
WO2007044050A3 (en) 1h-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
TNSN05197A1 (en) Pharmaceutical compositions comprising a combination of rapamycin or its derivative and pimecrolimus for the treatment of inflammation -and immunologically- mediated diseases
WO2004106293A3 (en) Oxazolyl - and thiazolyl - purine based tricyclic compounds.
ATE465164T1 (de) Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
CY1111693T1 (el) Αντιιικοι παραγοντες
ATE384061T1 (de) Imidazo- und thiazolopyridine als jak3-kinase- inhibitoren
BRPI0414066A (pt) 42-éster de rapamicina amorfo com ácido 3-hidróxi-2-( hidroximetil )-2-metilproipiÈnico e composições farmacêuticas que o contenha
BRPI0416692A (pt) inibidores heterocìclicos de mek e métodos de emprego destes
DE602005016718D1 (de) Ä1,2,4ütriazoloä4,3-aüpyridin-derivative zur behandlung hyperproliferativer erkrankungen
ATE417610T1 (de) Zusammensetzung enthaltend 6-ä3-(1-adamantyl)-4- methoxyphenylü-2-naphthanoesäure zur behandlung dermatologischer erkrankungen
EA200400944A1 (ru) Замещенные производные тетрациклина, фармацевтическая композиция и способ лечения субъекта с их использованием
ES2340502T3 (es) Compuestos de 1,4,8-triazaespiro(4,5)decan-2-ona sustituidos para el tratamiento de la obesidad.
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
BRPI0411673A (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto
DE60121986D1 (de) Triptpolidanaloge zur verendung in der behandlung von autoimmunbedingten und entzündlichen erkrankungen
BR0308184A (pt) Composição oftálmica compreendendo ascomicina
WO2004075846A3 (en) Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
WO2005011609A3 (en) Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
TW200740428A (en) Substituted propanamide derivatives and pharmaceutical compositions thereof
ATE150019T1 (de) Beta-mercapto-propanamidderivate verwendbar zur behandlung kardiovaskularer krankheiten oder erkrankungen
CR7835A (es) Uso de levocetiricina para el tratamiento de la rinitis alergica persistente
DOP2005000045A (es) Derivados de formamida para el tratamiento de enfermedades

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.